Massachusetts General Hospital (MGH) investigators have identified specific EEG (electroencephalogram) signatures that indicate when patients lose and regain consciousness under the general anesthetic drug propofol. Their report being published online in PNAS Early Edition is part of a major MGH-based investigation into the mechanisms behind general anesthesia and builds on the results of a November 2012 paper.
"We have discovered highly structured EEG patterns that indicate when people are sedated during administration of propofol, when they are unconscious and when they are able to regain consciousness," says Patrick Purdon, PhD, of the MGH Department of Anesthesia, Critical Care and Pain Medicine, lead author of the PNAS report. "These findings provide precise, neurophysiologically principled markers that can be used to monitor the state of a patient's unconsciousness under propofol general anesthesia."
Although it has been known since the 1930s that certain general anesthestics produce typical pattern changes in EEG – recordings of the brain's electrical activity taken by electrodes placed on the scalp –specific patterns that indicate the loss and recovery of consciousness under anesthesia have never been identified. Monitoring of patients under anesthesia has focused on tracking vital signs such as changes in heart rate and blood pressure. Dosing of anesthetic drugs has been based on target or measured concentrations in the blood or the lungs, even though the primary effects of the drugs are in the brain and central nervous system.
Although the raw EEG and its frequency components can give direct, detailed information about brain states under anesthesia, Purdon explains, most current brain monitoring systems reduced the complex EEG signal to a single number that could not accurately reflect the underlying physiological processes that create the patterns. Indeed clinical studies have found current depth-of-anesthesia monitors to be no more effective at predicting awareness than monitoring drug levels in the lungs.
The November 2012 report from a team led by Purdon, published in PNAS Plus, found a pattern of brain activity that appeared to indicate the loss of consciousness under propofol, but that study was conducted in only three patients and measured brain activity via electrodes previously implanted into participants' brains for the treatment of epilepsy. The current study took highly detailed EEG readings of 10 healthy volunteers during propofol general anesthesia. When used clinically, propofol usually induces unconsciouness within less than a minute, making detailed tracking of EEG changes virtually impossible. But for this study, propofol dosage was slowly increased to a target level over a period of one hour, then slowly decreased over a second hour.
During that time, study participants listened to prerecorded sounds – either words or clicks – presented every four seconds and were asked to identify the type of sound they heard by pressing a button. A loss of response to clicks indicated the onset of sedation, and a persistant loss of response to words was considered loss of consciousness. The readings taken throughout the two-hour study period identified characteric changes in EEG patterns that indicated sedation, loss and return of consciousness, and a state of profound unconsciousness.
An important observation related to interactions between the signaling frequencies measured by EEG. One particular pattern, which the researchers call "trough-max," occurred during transitions in consciousness, particularly right before consciousness returned. Another pattern called "peak-max" was observed at the highest propofol dosage and signified the deepest levels of unconsciousness. Purdon and his colleagues believe that the peak-max signal pattern corresponds with the brain state identified in the November PNAS Plus report, which represented a disruption in communication between different parts of the brain.
"The consequences of this could be huge, because it would mean we have found a brain state where we know patients will be unconscious and could monitor that brain state in the operating room using EEG," Purdon says. "Appearance of the trough-max pattern would provide a way to predict when patients might be regaining consciousness. With these fundamental neurophysiological markers of the sedative and unconscious states under propofol and with some existing EEG equipment, we can start monitoring these EEG signatures when administering propofol immediately."
An instructor in Anesthesia at Harvard Medical School, Purdon adds, "We are working on new monitoring technologies to develop of EEG monitors that will display the peak-max and trough-max patterns, helping us ensure when patients are unconscious and predict when they might be regaining consciousness. We also are working to characterize similar EEG patterns for other anesthetic agents and to develop a program to train anesthesiologists how to interpret the EEG in terms of the neurophysiology and mechanisms for different drugs." A patent for anesthesia monitoring based on these findings is pending.
Emery N. Brown, MD, PhD, MGH anesthetist, the Warren M. Zapol Professor of Anaesthesia at Harvard Medical School and the study’s senior author adds, "This work helps establish the basic and clinical science needed to set standards for use of the EEG to track the brain states of patients under general anesthesia. Reading the EEG will allow anesthesia caregivers to adjust dosage more precisely and thereby help reduce the incidence of cognitive dysfunction and delirium following anesthesia as well as making unintended regaining of awareness while under anesthesia a phenomenon of the past." Brown is also a professor in the MIT Department of Brain and Cognitive Sciences and the Institute of Medical Engineering and Science.
The study was supported by National Institutes of Health Director's Pioneer Award (DP1-OD003646) to Brown, NIH New Innovator Award DP2-OD006454 to Purdon, and additional NIH grants R01-MH071847, K25-NS057580 and R01-EB006385.
Massachusetts General Hospital (www.massgeneral.org), founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine. In July 2012, MGH moved into the number one spot on the 2012-13 U.S. News & World Report list of "America's Best Hospitals."
Sue McGreevey, email@example.com, 617-724-2764